Liver resident NK1.1 ؉ T cells are supposed to play a pivotal role in the onset of inflammatory liver injury in experimental mouse models such as concanavalin A (Con A)-induced hepatitis. These cells, expressing the adhesion receptor, CD44, are largely depleted from the liver by a single intravenous injection of low-molecular-weight fragments of hyaluronic acid (LMW-HA). Here, we report that LMW-HA pretreatment protected mice from liver injury in several models of T-cell-and macrophage-dependent, tumor necrosis factor ␣ (TNF-␣)-mediated inflammatory liver injury, i.e., from liver injury induced by either Con A or
Increased synthesis and degradation of components of the extracellular matrix are hallmarks of chronic inflammation and tissue fibrosis. A major component of the extracellular matrix that undergoes dynamic regulation during inflammation is the glycosaminoglycan, hyaluronic acid (HA) (for review, see Laurent 1 ). Analysis of serum HA has a prognostic value in liver disease, liver allograft rejection, 2, 3 and various inflammatory conditions, such as rheumatoid arthritis and sepsis. 3 The appearance of HA fragments in serum during inflammatory processes results from both enhanced degradation and increased production of HA. 4, 5 Proinflammatory cytokines such as tumor necrosis factor ␣ (TNF-␣) and interleukin (IL)-1 induce endothelial expression of HA and increase CD44-dependent adhesion of T lymphocytes. 6 CD44 is a cell adhesion molecule 7 and the principal receptor of HA. 8 Activation of CD44 occurs on activated T cells [9] [10] [11] and monocytes/macrophages, 12, 13 and is inducible by T-cell receptor activation 11 and by TNF. [13] [14] [15] CD44 is required for T-cell extravasation into inflamed tissue rather than for normal recirculation of T cells to and from secondary lymphoid organs. 16 Neutralizing antibodies against CD44 have been shown to prevent T-cell infiltration into inflamed sites. 16 Accordingly, these antibodies also attenuated leukocyte infiltration, tissue edema, and other disease symptoms in experimental models of murine arthritis. [17] [18] [19] Moreover, CD44 knockout mice were protected from the vascular leak syndrome induced in lung and liver by administration of IL-2. 20 However, although CD44 functions as a cell adhesion molecule, there is also substantial evidence that CD44 is a potent signaling receptor. Stimulation of CD44 leads to activation and induction of effector functions in T cells [21] [22] [23] and macrophages. [24] [25] [26] [27] [28] It is noteworthy that high-and lower-molecular-weight HA exhibit different biological activities. The low-molecularweight HA (LMW-HA) stimulates murine macrophages to activate nuclear factor-B (NF-B). Consequently, LMW-HA has been shown to stimulate the expression of NF-B-dependent genes 29 in cultured macrophages, such as TNF-␣ and IL-1␤, 25 ,26 chemokines 27 and inducible nitric oxide synthase (iNOS). 28 In primary rat liver cell cultures, LMW-HA stimulated the expression of iNOS in endothelial and Kupffer cells, and it potentiated the interferon gamma (IFN-␥)-stimulated formation of iNOS mRNA and protein in hepatocytes, endothelial, Kupffer, and stellate cells. 30 Considering the proinflammatory properties of LMW-HA in vitro, it is somewhat surprising that the principal ligand of CD44, i.e., high-molecular-weight HA (HMW-HA), is of therapeutic value in different human pathologies. HMW-HA is therapeutically used for treatment of human inflammatory diseases such as osteoarthritis, rheumatoid arthritis, and wound healing (reviewed in Goa 31 ).
Despite its proinflammatory properties, LMW-HA has also been described to attenuate inflammatory disorders in experimental animal models. Pretreatment with T-cell-and macrophage-activating LMW-HA has been shown to protect animals from allograft rejection 32 and acute liver injury induced by administration of Propionibacterium acnes and lipopolysacchairde (LPS). 33 The hepatoprotective effect has been attributed to a significant reduction of liver NK1.1 ϩ T cells (NK T-cells), a distinct subpopulation of CD44-positive, T-cellreceptor intermediate and NK1.1-positive T cells. 33 The authors hypothesized that these NK T cells specifically adhere in the sinusoids of the liver via CD44-HA interactions. Consequently, intravenous injection of LMW-HA resulted in a blockade of CD44-HA interaction between leukocytes and endothelial cells within the liver, leading to the observed reduction of liver NK T cells. Liver NK T cells have been closely related to the development of acute hepatitis induced by the mitogenic plant lectin, concanavalin A (Con A). [34] [35] [36] Because of the apparent dependence of Con A hepatitis on NK T cells, we wondered whether LMW-HA is able to protect animals from Con A-induced hepatitis. Furthermore, the current study was addressed to investigate possible hepatoprotective actions in other experimental models of liver injury as well. We demonstrate that LMW-HA exerts its hepatoprotective actions in a wide spectrum of different models of T-cell-and macrophage-dependent acute liver inflammation (Con A, 37, 38 Pseudomonas aeruginosa exotoxin A [PEA], 38, 39 and PEA/ LPS 40 ) . Surprisingly, LMW-HA also protected mice from liver injury directly induced by recombinant murine (rmu)TNF in D-galactosamine (GalN)-sensitized mice. Thus, we provide new insights into the biological effects of LMW-HA fragments in vivo, by showing that, apart from NK T-cell depletion, they also provide cytoprotection against TNF-induced cell death.
MATERIALS AND METHODS
Animals. Six-to 8-week-old male BALB/c mice were obtained from the institute's internal breeding house. LPS-resistant C57BL/10 ScCr mice and the corresponding LPS-sensitive C57BL/10 ScSn mice 41 were kindly provided by Dr. M. A. Freudenberg, Max-Planck-Institute for Immunobiology, Freiburg, Germany. They were maintained under controlled conditions (22°C, 55% humidity, 12-hour dark/ light rhythm), and had free access to standard chow and water. All animals received humane care in compliance with the National Institutes of Health guidelines and in accord with the legal requirements in Germany.
Animal Treatments. All reagents were injected in a total volume of 250 L per 25-g mouse, except for LMW-HA, which was intravenously injected in a total volume of 500 L per mouse. All reagents were dissolved in pyrogen-free saline. Either 0.5% LMW-HA from bovine vitreous humor (molecular weight, 45-90 kd) (Sigma, Deisenhofen, Germany) or saline were intravenously injected 12 hours before treatment with the corresponding hepatotoxin. LPS content of LMW-HA stock solutions was determined with the help of a commercially available limulus amebocyte lysate kit (Coatest Endotoxin, Chromogenix AB, Mö lndal, Sweden). LMW-HA pretreatment was followed by injection of: 1) 20 mg/kg Con A (Sigma) intravenously; 2) 85 g/kg PEA (Sigma) intravenously; 3) 10 g/kg PEA intravenously and 10 g/kg LPS from Salmonella abortus equi, S form (Metalon GmbH, Ragow, Germany) intraperitoneally; 4) 700 mg/kg GalN (Roth GmbH, Karlsruhe, Germany) intraperitoneally and 8 g/kg rmuTNF (kindly provided by Dr. G. R. Adolf, Bender Co., Vienna, Austria) intravenously. For elucidation of LMW-HAinduced as compared with LPS-induced hepatotoxicity, we injected 700 mg/kg GalN intraperitoneally together with either 500 L 0.5% LMW-HA intravenously or with 6.5 g per kilogram of LPS intraperitoneally. In the case of NF-B inhibition, pyrrolidine dithiocarbamate (PDTC) (Sigma) was intravenously injected in a dose of 100 mg/kg 30 minutes before LMW-HA treatment. Early pretreatment with rmuTNF was performed using a dose of 10 g/kg, which was intravenously injected 12 hours before Con A, PEA, or GalN/ rmuTNF.
Sampling of Material. For determination of plasma cytokines (TNF, IFN-␥, IL-2, IL-6, and IL-10) by enzyme-linked immunosorbent assay (ELISA), blood was taken from the tail vein. Eight (in the case of Con A or GalN/rmuTNF) or 12 (in the case of PEA or PEA/LPS) hours after treatment with the corresponding hepatotoxin, mice were lethally anesthetized with 150 mg/kg Nembutal (Sanofi-Ceva, Wirtschaftgenossenschaft deutscher Tierärzte eG, Hannover, Germany), intravenously, containing a dose of 15 mg/kg heparin (Sigma). Then, blood was withdrawn by cardiac puncture of the right ventricle and immediately centrifuged for 4 minutes at 4°C and 13,000g. Plasma samples were stored at Ϫ80°C until detection of cytokines by ELISA and measurement of enzyme activities of alanine transaminase (ALT) and aspartate transaminase (AST) (see below). The livers were removed and one part was frozen in liquid nitrogen for: 1) detection of oligonucleosomal-bound DNA fragments; 2) determination of intrahepatic caspase-3 activity; 3) quantification of intrahepatic TNF production; 4) measurement of intrahepatic mRNA levels of TNF; or 5) analysis of intrahepatic NF-B activation by an electrophoretic mobility shift assay (EMSA). Another small part was embedded in Tissue-TEC and stored at Ϫ20°C until immunofluorescent staining.
Proliferation Assay. Spleen cells from male BALB/c mice were isolated by pressing the spleen through a steel grid into RPMI 1640 medium. Red blood cells were lysed by 5-minute incubation with 0.17 mol/L NH 4 Cl at room temperature; spleen cells were washed twice with RPMI 1640; and 10 6 cells were incubated in RPMI 1640, 10% fetal calf serum, 50 mol/L mercaptoethanol for 24 or 48 hours at 37°C, 5% CO 2 with: 1) medium alone; 2) 2 g/mL Con A; or 3) 2 g/mL Con A and different concentrations of LMW-HA (200, 500, or 1,000 g/mL). Proliferation was assayed using the reduction of the dye, 3-[4,5-dimethyldiyzol-2-yl]-2,5 diphenyltetrazolium (5 mg/mL phosphate-buffered saline [PBS]; Sigma Chemical Co.) by viable cells as described elsewhere. 42 Analysis of Liver Enzymes. Liver injury was quantified by measurement of plasma enzyme activities of ALT and AST according to Bergmeyer, 43 using an automated procedure.
Plasma Cytokine Determination by ELISA. Detection of TNF, IFN-␥, IL-2, IL-6, and IL-10 was performed on flat-bottomed, high-binding, polystyrene microtiter plates (Nunc, Roskilde, Denmark) using specific rat anti-mouse monoclonal antibody (mAb) pairs purchased from PharMingen (Hamburg, Germany).
DNA Fragmentation. Detection of oligonucleosome-bound DNA fragments was performed using an ELISA kit (Boehringer Mannheim, Mannheim, Germany). Briefly, the cytosolic fraction (13,000-g supernatant) from approximately 200 g of liver was employed as antigen source in a sandwich ELISA with a primary anti-histone antibody coated to the microtiter plate and a secondary peroxidaseconjugated anti-DNA antibody. In situ detection of DNA fragments was performed using a terminal deoxynucleotidyl transferase-medi-ated deoxyuridine triphosphate nick-end labeling (TUNEL) test (Boehringer Mannheim).
Quantification of Intrahepatic TNF. Livers were disintegrated in icecold Ripa buffer (150 mmol/L NaCl, 5 mmol/L EDTA, 50 mmol/L Tris [pH 7.4]), containing protease inhibitors, DNase, and detergents (0.3% Triton X-100, 0.03% sodium dodecyl sulfate, 0.3% sodium deoxycholate), resulting in a 50% (wt/wt) liver homogenate, which was then incubated on ice for 30 minutes and centrifuged at 15,000g for 30 minutes at 4°C. The supernatants were subjected to a second centrifugation at 15,000g for 20 minutes at 4°C. Supernatants were harvested and stored at Ϫ80°C until determination of intrahepatic TNF protein by ELISA. 38 TNF in liver lysates was detected by a murine ELISA kit purchased from RD systems (Wiesbaden, Germany). Liver lysates were adjusted to equal protein concentrations after protein was quantified by the Bradford method, as used in the Bio-Rad protein assay (Bio-Rad, Munich, Germany).
Real-Time Reverse-Transcription Polymerase Chain Reaction for TNF mRNA in Liver Tissue. RNA was isolated from pieces of ϳ25 mg liver tissue by the use of a RNA purification kit (Qiagen, Hilden, Germany). One microgram of RNA was employed for synthesis of cDNA, using first-strand buffer, dithiothreitol (DTT), oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer, recombinant ribonuclease inhibitor, and RNase H Ϫ reverse transcriptase from GibcoBRL (Life Technologies GmbH, Karlsruhe, Germany), and deoxynucleosidtriphosphates from Invitrogen (Groningen, the Netherlands). Synthesis of cDNA was performed using a MWG-Biotech Primus 96 plus thermo cycler (MWG-Biotech, Ebersberg, Germany). For real-time reverse-transcription polymerase chain reaction (RT-PCR), we used the Light Cycler FastStart DNA Master SYBR Green I method, according to the manufacturer's instructions (Roche Diagnostics GmbH, Mannheim, Germany). Primers were selected for murine ␤-actin and TNF (GibcoBRL). ␤-Actin: 5Ͼ TGG AAT CCT GTG GCA TCC ATG AAA; 3Ͼ TAA AAC GCA GCT CAG TAA CAG TCC G. TNF: 5Ͼ ATG AGC ACA GAA AGC ATG ATC; 3Ͼ GTC TGG GCC ATA GAA C. Forty cycles of real-time RT-PCR were run as follows. ␤-Actin: denaturation, 95°C, 1 second; primer annealing, 56°C, 7 seconds; polymerization, 72°C, 15 seconds. TNF: denaturation, 95°C, 1 second; primer annealing, 57°C, 7 seconds; polymerization, 72°C, 10 seconds. mRNA levels were calculated using the comparative C t method 44 and normalization to ␤-actin. To confirm amplification specificity, PCR products were subjected to a melting-curve analysis. Quantification is reported as the x-fold difference relative to a calibrator cDNA from saline-treated mice. Because TNF mRNA was not detectable within livers of salinetreated mice, signals that exceeded a ⌬C t of 15 were arbitrarily set to 1-fold to enable a calibration. The relation to this arbitrary 1-fold is represented by the data described as "x-fold increase of mRNA."
Intrahepatic Caspase-3 Activity Determination. Liver tissue was disintegrated in ice-cold caspase-3 buffer (100 mmol/L HEPES, 10% sucrose, 0.1% Chaps, 1 mmol/L EDTA [pH 7.5]), resulting in a 50% (wt/wt) liver homogenate. The liver homogenates were centrifuged at 15,000g for 15 minutes at 4°C. The resulting supernatants were then used for caspase-3 activity determination, as described previously. 45 Protein concentrations of the supernatants were quantified by the Bradford method, as used in the Bio-Rad protein assay (BioRad, Munich, Germany). Briefly, 100 g total protein was incubated in a total volume of 150 L caspase-3 buffer with 10 mmol/L DTT and the fluorescent substrate, N-Ac-DEVD-AMC, 25 mol/L (Biomol, Hamburg, Germany), for 2 hours at 30°C. Enzyme activity was quantified by the release of AMC from N-Ac-DEVD-AMC with a Tecan Spectra Fluor (Tecan, Crailsheim, Germany) (excitation wavelength, 380 nm; emission wavelength, 460 nm).
Hematoxylin-Eosin Staining of Liver Sections. Following fixation of the livers with 4% formalin/phosphate-buffered saline (PBS), livers were sliced and stained with hematoxylin-eosin.
Preparation of Nuclear Extracts. Nuclear extracts from frozen liver sections were prepared as described elsewhere. 46 Braun, Biotech, Merck Eurolab GmbH, Nü rnberg, Germany). The homogenate was transferred to a polypropylene centrifuge tube and incubated on ice for 10 minutes. After centrifugation, the pellet was resuspended in 1.4 mL of buffer A. Ninety microliters of Nonidet P-40 (10%) was added, followed by 10 seconds of vigorous vortexing and incubation on ice for 10 minutes. After centrifugation (12,000g for 30 seconds), the supernatant was removed, and the nuclear pellet was extracted with hypertonic buffer B (20 mmol/L HEPES [pH 7.9], 0.4 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L DTT, 1 mmol/L phenylmethylsulfonyl fluoride) by shaking at 4°C for 60 minutes. The extract was centrifuged at 12,000g, and the supernatant was frozen at Ϫ70°C. The protein concentration was determined by the Bradford method.
EMSA. A 22-mer double-stranded oligonucleotide probe containing a consensus binding sequence for NF-B (5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј; Promega, Heidelberg, Germany) was 5Ј-end-labeled with [␥ 32 P]-ATP (10 Ci) using T4 polynucleotide kinase. Five micrograms of nuclear protein was incubated in a 15-L reaction volume (containing 10 mmol/L Tris-HCl (pH 7.5), 5 ϫ 10 4 cpm radiolabeled oligonucleotide probe, 2 g of poly(dI-dC), 4% glycerol, 1 mmol/L MgCl 2 , 0.5 mmol/L EDTA, 50 mmol/L NaCl, and 1 mmol/L DTT) for 20 minutes at room temperature. Nucleoproteinoligonucleotide complexes were resolved by electrophoresis (4.5% nondenaturing polyacrylamide gel; 100 V) and detected by phosphorimaging (Packard, Meriden, CT). Specificity of the DNA-protein complex was confirmed by competition with a 100-fold excess of unlabeled NF-B and AP-2 (5Ј-GAT CGA ACT GAC CGC CCG CGG CCC GT-3Ј; Promega) binding sequences, respectively.
Immunofluorescent Staining and Confocal Laser Imaging. Ten-micrometer sections of livers were thawed onto glass slides, air-dried, and subsequently fixed in acetone-methanol (1:1) for 10 minutes at 4°C. After washing, slides were blocked with PBS containing 3% bovine serum albumin for 1 hour and then incubated overnight with either a polyclonal rabbit anti-mouse-TNF Ab (Genzyme, Rü sselsheim, Germany) together with a rat mAb against murine macrophages (clone BM8; Dianova, Hamburg, Germany), or with rat anti-mouse mAb against mouse CD4 (clone L3T4; Pharmingen, Hamburg, Germany), or with rat anti-mouse CD44 mAb (clone KM114; Pharmingen), with a polyclonal rabbit anti-mouse-RelA of the NF-B complex (Oncogene, Cambridge, MA). Binding of primary anti-macrophage, anti-CD4, and anti-CD44 mAbs was detected with a goat anti-rat secondary antibody tagged with Texas Red (Dianova). Binding of primary anti-TNF Ab was detected using swine anti-rabbit-IgG tagged with fluorescein isothiocyanate (Dianova), and binding of primary anti-RelA mAb with Cy3-labeled goat anti-rabbit Ab (Dianova). The secondary antibodies were dissolved in PBS/bovine serum albumin 3%, and slides were incubated with the corresponding antibodies for 1 hour at room temperature. After rinsing with PBS, sections were cover-slipped with 10% glycerol/PBS (pH 8.6). Then immunofluorescence was detected using confocal laser scanning microscopy (BioRad MRC 1000). To exclude unspecific binding of the primary or the secondary antibody, sections were either incubated with the corresponding isotype control instead of the primary antibody or with the secondary antibody only.
Semiquantitative Analysis of CD45 ؉ Leukocyte Accumulation. Liver sections were stained with a directly fluorescein isothiocyanate-labeled rat anti-mouse antibody (clone 104) specific for CD45, purchased from PharMingen. The number of CD45 ϩ leukocytes was quantified by 3 independent investigators blinded to animal treatment and using a Leitz Aristoplan microscope (Leitz, Wetzlar, Germany). All CD45 ϩ leukocytes in the sinusoids as well as in large hepatic vessels in a randomly defined field were counted. Data are expressed as the total number of CD45 ϩ leukocytes per square millimeter.
Statistical Analysis. Data of transaminases, cytokines, DNA fragmentation, TNF mRNA levels, caspase-3 activity, and CD45 ϩ leukocytes in liver sections are expressed as the mean Ϯ SEM and analyzed by one-way ANOVA, followed by Dunnett's multiple-comparison test. Survival curves were compared using the log rank test. All statistical analyses were calculated with the computer program, Prism (GraphPad Software, Inc., San Diego, CA).
RESULTS

LMW-HA Confers Resistance Against T-Cell-and Macrophage-
Dependent Hepatic Failure. Male BALB/c mice were treated either with Con A, PEA, or PEA/LPS 12 hours after pretreatment with either saline or 0.5% LMW-HA. As shown in Table 1 , LMW-HA protected mice from liver injury in all 3 models, as assessed by a significant inhibition of plasma ALT release. Furthermore, we detected hepatic DNA fragmentation as a second marker of hepatocellular death. As shown clearly in the model of Con A-induced hepatic failure, LMW-HA injection significantly reduced the induction of DNA fragmentation, detected either in liver homogenates by ELISA (Fig. 1A) or in situ on liver sections by TUNEL of fragmented DNA and subsequent analysis by confocal laser imaging (Fig. 1B) . To further demonstrate an impact of LMW-HA preteatment on survival, we chose the model of PEA-induced hepatic failure, which, in contrast to the Con A model, is associated with death of the animals. 39 As shown in Fig. 2 , LMW-HA pretreatment before PEA injection significantly prolonged survival. However, despite prolongation of survival, LMW-HA pretreatment was not life-saving. This might be explained by PEA-induced inhibition of protein synthesis. 47 LMW-HA Does Not Affect Con A-Induced Activation of Lymphocytes. Con A-and PEA-induced hepatic failure depend on the activation of T cells. 37, 39 To analyze whether LMW-HA reduces the number of total peripheral leukocytes, we injected LMW-HA into male BALB/c mice and counted leukocytes in the peripheral blood 12 hours after treatment. We further analyzed the proliferative response of isolated spleen cells to Con A in the presence of LMW-HA in vitro. LMW-HA injection did not cause depletion of leukocytes in the peripheral blood (data not shown), and the Con A-stimulated response of spleen cells was only marginally reduced by LMW-HA (the control incubated with medium alone was set at 100%; proliferation rate was determined after 24 hours; Con A: 251% Ϯ 8%; 1,000 g/mL LMW-HA ϩ Con A: 207% Ϯ 2.3%; 1,000 g/mL LMW-HA: 121.5% Ϯ 1.8%).
Effect of LMW-HA on Con A-Induced Accumulation of CD4 ؉ and CD44 ؉ Cells. LMW-HA has been described to deplete hepatic NK T cells from the liver. 33 However, immunofluorescent staining of CD4 and CD44 demonstrated that LMW-HA pretreatment did not attenuate Con A-induced hepatic accumulation of either CD4 ϩ or CD44 ϩ inflammatory cells (Fig. 3) .
Cytokine Plasma Levels After LMW-HA Pretreatment. To investigate the effect of LMW-HA pretreatment on the production of proinflammatory cytokines, we measured plasma levels of IL-2, TNF, IL-6, IL-10, and IFN-␥ by ELISA. LMW-HA pretreatment significantly reduced maximal plasma TNF, IL-6, IL-10, and IFN-␥ levels in PEA/LPS-treated mice (Fig. 4A) . In contrast, we neither observed a reduction of the lymphocyte- NOTE. Male BALB/c mice, either pretreated with saline or 500 L of 0.5% LMW-HA, were treated with Con A, PEA, or PEA/LPS 12 hours later. In the case of Con A, liver damage was measured 8 hours, in the case of PEA and PEA/LPS 12 hours, after challenge by determination of plasma ALT levels. Data are expressed as the mean Ϯ SEM; n ϭ 3.
*P Ͻ .05 vs. saline pretreatment.
FIG. 1. LMW-HA significantly attenuates hepatic injury induced by Con A treatment. Either saline-or LMW-HA-pretreated BALB/c mice were intravenously injected with Con A. Livers were removed 8 hours after Con A treatment for determination of hepatic damage by either (A) oligonucleosome ELISA, which detects fragmented DNA (the value of saline-treated mice was set to 1, and all other values were calculated accordingly and expressed as mean value of x-fold induction vs. saline-treated mice; n ϭ 5; * P Ͻ .05 vs. Con A), or by (B) the TUNEL method, which detects 3Ј OH ends of fragmented DNA in hepatic nuclei of frozen liver sections (see Materials and Methods). Saline-treated mice only showed rarely detectable, intrasinusoidally located TUNEL-positive cells. Many parenchymal cell nuclei in the focal necrosis-like areas of the Con A hepatitis liver were stained with the TUNEL method, whereas such TUNEL-positive cells were only scarcely detectable in LMW-HA-pretreated Con A-challenged mice.
derived cytokines, IL-2 and IFN-␥, nor of the macrophagederived cytokines, TNF, IL-6, and IL-10, in LMW-HA-pretreated, Con A-injected mice (Fig. 4B) . However, using quantitative analysis of intrahepatic mRNA levels by real-time RT-PCR, LMW-HA induced a significant suppression of intrahepatic TNF mRNA levels in both models (PEA/LPS: Fig. 5A ; Con A: Fig. 5B ). Thus, plasma levels of TNF only poorly reflect intrahepatic changes of the expression of this cytokine.
PEA/LPS-and Con A-Induced Activation of NF-B Is Inhibited by
LMW-HA. NF-B is a critical transcription factor for the induction of cytokine gene expression under conditions of inflammation. 48 We therefore analyzed whether LMW-HA alters NF-B activation after either PEA/LPS or Con A injection, thereby attenuating intrahepatic TNF production. EMSA (Fig.  6 ) revealed that within 2 hours after treatment, PEA/LPS (Fig.  6A, lanes 3 and 4) , as well as Con A (Fig. 6B, lanes 3 and 4) , induce enhanced DNA binding of NF-B in hepatic nuclei as compared with saline-treated controls (Fig. 6A and 6B , lane 2). Fourteen hours after injection of LMW-HA alone (Fig. 6A and 6B, lane 1), NF-B DNA-binding activity was only marginally enhanced as compared with saline-injected animals. Both PEA/LPS- (Fig. 6A, lanes 5 and 6) as well as Con A-induced (Fig. 6B, lanes 5 and 6) In the case of either saline-or LMW-HA-pretreated, Con A-injected mice, TNF, IL-2, IL-6, and IL-10 were determined 2 hours after Con A challenge, whereas IFN-␥ was assessed after 8 hours. Data are expressed as the mean Ϯ SEM; n ϭ 3; *P Ͻ .05 vs. salinepretreated controls.
HEPATOLOGY Vol. 34, No. 3, 2001 hibited by pretreatment with LMW-HA. Specificity of the EMSA is shown by the capability of unlabeled oligonucleotides specific for NF-B (Fig. 6A and 6B, lane 7) , but not of oligonucleotides specific for AP-2 ( Fig. 6A and 6B, lane 8) , to down-regulate binding of the specific probe. Thus, LMW-HA inhibits the ability of proinflammatory stimuli to activate hepatic NF-B translocation, which consequently down-regulates the expression of NF-B-regulated genes, e.g., TNF.
LMW-HA Confers Resistance Against TNF-Induced Hepatocellular
Cell Death In Vivo. As shown above, LMW-HA induces resistance of intrahepatic leukocytes to respond to proinflammatory stimuli. However, we wondered whether the hepatoprotective effect of LMW-HA is restricted to its effects on inflammatory cells. We therefore injected LPS-resistant C57BL/10 ScCr and LPS-sensitive C57BL/10 ScSn mice (Fig.  7A) , as well as BALB/c mice (Fig. 7B) , with 8 g rmuTNF under conditions of transcriptional arrest induced by GalN after pretreatment with saline or LMW-HA. As assessed by a significant attenuation of ALT release in plasma samples 8 hours after injection of GalN/rmuTNF in LMW-HA-versus saline-pretreated mice (Fig. 7A) , we observed that LMW-HA also protected mice from hepatocyte cell death induced by directly administered rmuTNF. The usage of LPS-resistant mice revealed that the hepatoprotective effect was not caused by LPS contamination (Fig. 7A) . (Fig. 7C) .
LMW-HA Greatly Reduces Histopathologic Changes on GalN/
rmuTNF Treatment. Liver histology appeared normal in either saline- (Fig. 8A) , LMW-HA- (Fig. 8B) , or PDTC- (Fig. 8C ) injected mice. In contrast, treatment of mice with GalN/ rmuTNF showed extensive confluent hepatocyte necroses that were located in the pericentral area ( Fig. 8D and 8G) . Similar to the histopathology seen in human alcoholic hepatitis, necrotic hepatocytes were often surrounded by polymorphonuclear neutrophils. LMW-HA pretreatment greatly reduced the histopathologic alterations induced by GalN/ rmuTNF ( Fig. 8E and 8H) . Only a few Councilman-like bodies were scattered throughout the hepatic parenchyma. Inhibition of NF-B activation by injection of PDTC before LMW-HA restored the sensitivity toward GalN/rmuTNF, which is reflected by extensive histopathologic changes comparable with the situation in GalN/rmuTNF-treated animals ( Fig. 8F and 8I ).
LMW-HA Inhibits GalN/rmuTNF-Induced Activation of Caspase-3.
According to our data concerning the effect of LMW-HA on GalN/rmuTNF-induced transaminase release and liver damage, LMW-HA significantly prevented the increase of caspase-3 activity induced by GalN/rmuTNF (Fig. 9) . Caspase-3 was determined 8 hours after injection of GalN/ rmuTNF. Activity of caspase-3 was quantified by fluorogenic measurement of the proteolytic cleavage of the caspase-3 substrate, N-Ac-DEVD-AMC. Inhibition of NF-B abolished the effect of LMW-HA. It restored the ability of rmuTNF to induce caspase-3 activity (Fig. 9) .
LMW-HA Significantly Reduced GalN/rmuTNF-Induced Accumulation of CD45 ؉ Leukocytes. Semiquantitative analysis of GalN/ rmuTNF-induced hepatic accumulation of CD45 ϩ leukocytes by counting CD45 ϩ leukocytes in liver sections revealed that pretreatment with LMW-HA significantly reduced GalN/ rmuTNF-induced hepatic accumulation of CD45 ϩ leukocytes (Fig. 10) . LMW-HA-induced inhibition of leukocyte accumulation was restored by NF-B inhibition with PDTC (Fig. 10) .
LMW-HA Activates Kupffer Cells to Produce TNF. In vitro studies already demonstrated that LMW-HA has macrophage-activating properties, because it induces the expression of proinflammatory proteins in cultured macrophages (i.e., iNOS, chemokines, TNF). [24] [25] [26] [27] [28] To study the in vivo effects of LMW-HA, we injected hyaluronan fragments into mice to investigate their TNF-inducing activity. In vivo injection of LMW-HA induced the production of TNF as assessed by timecourse analysis of TNF plasma levels. Significantly elevated TNF plasma levels were detectable as early as 1 hour after LMW-HA treatment and were followed by a rapid decline (saline-treated: not detectable; 1 hour after LMW-HA: 87.4 Ϯ 19.4 pg/mL; 2 hours after LMW-HA: not detectable).
Moreover, LMW-HA activated hepatic macrophages, i.e., Kupffer cells, to produce TNF in vivo (Fig. 11) . As shown by double-immunofluorescent staining with a pan-macrophage marker and a polyclonal anti-TNF antibody and subsequent analysis by confocal laser imaging, the Kupffer cells clearly produced TNF upon stimulation with LMW-HA, whereas no such TNF staining was detectable in saline-treated mice. A higher magnification of an intrahepatic macrophage clearly demonstrated intracellular deposits of TNF, as shown by the green fluorescence located in the cytoplasm of the scanned Kupffer cell (inset of Fig. 11, LMW-HA [1 hour] ). Inhibition of NF-B activation by PDTC, which was injected 30 minutes before LMW-HA, completely abrogated the intrahepatic production of TNF, as shown by the lack of TNF staining (Fig.  11) . Again, to exclude side effects of contaminating LPS, we injected LPS-resistant C57BL/10 ScCr mice with LMW-HA and quantified intrahepatic TNF production by ELISA of liver lysates. 38 LMW-HA fragments induced a significant increase of intrahepatic TNF 1 hour after injection to C57BL/10 ScCr mice (saline: 48.8 Ϯ 5.5 pg/mL; LMW-HA: 226 Ϯ 34.3 pg/ mL; P Ͻ .05 vs. saline).
Pretreatment With rmuTNF Protects Mice From TNF-Mediated
Hepatocellular Damage. Because LMW-HA induced TNF production by Kupffer cells and because TNF is known to confer resistance toward TNF hepatotoxicity, 49 we wondered whether TNF would also protect mice in our TNF-dependent models of liver toxicity. Therefore, we pretreated mice with 10 g/kg of rmuTNF before Con A, PEA, or GalN/rmuTNF. As shown in Fig. 12 , pretreatment with rmuTNF led to a significant attenuation of transaminase release in either experimental model of TNF-dependent hepatocellular cell death, demonstrating that TNF itself can protect mice from TNFmediated liver cell death. 
LMW-HA Treatment Induces Translocation of NF-B Into Hepatic
Nuclei. It is well known that TNF is a potent inducer of NF-B translocation. This prompted us to investigate if LMW-HA also induces translocation of NF-B into hepatic nuclei. We therefore performed immunofluorescence staining with a polyclonal antibody directed against the p65 (RelA) subunit of the NF-B complex. Mice treated with saline only did not show any NF-B staining of hepatic nuclei (Fig. 13) , whereas weak cytoplasmatic staining of hepatocytes was detectable. In contrast, livers of LMW-HA-treated mice exhibited strong NF-B staining of hepatocyte nuclei (Fig. 13) , indicating that the p65 subunit of NF-B was translocated into the nuclei. This process was inhibited by pretreatment with the NFB inhibitor, PDTC (Fig. 13) . As a positive control, we analyzed the NF-B-activating properties of TNF in livers of rmuTNFtreated mice. Figure 13 shows that rmuTNF was also able to induce translocation of NF-B into hepatic nuclei (Fig. 13) .
LMW-HA Is Hepatotoxic Under Conditions of Impaired Protein
Synthesis. As shown above, LMW-HA is able to activate NF-B and to induce intrahepatic TNF production. Consequently, we wondered whether LMW-HA would be hepatotoxic when coadministrated with GalN, a well-known inhibitor of hepatic transcription. Figure 14 shows that GalN/LMW-HA, like GalN/LPS, induced the release of transaminases in mice. These data clearly demonstrate the proinflammatory potency of hyaluronan fragments.
DISCUSSION
HA is a complex heteropolysaccharide and a ubiquitous component of the extracellular matrix. Initially, it was implicated only in macrostructural functions, but in recent years, it has clearly been shown that LMW-HA in particular contributes to a wide array of biological as well as pathologic processes. Accumulation of hyaluronate fragments is a common feature of different pathologic processes affecting the liver, 50, 51 as well as many other organs, such as kidneys, joints, and lung. 3 Our current report further supports the hypothesis that the lower-molecular-weight form of hyaluronic acid, i.e., LMW-HA, has potent biological effects in vivo, as it dosedependently protected animals from TNF-mediated acute liver failure.
Activation of inflammatory cells is known to induce the interaction of CD44 on inflammatory cells, with its ligand, HA, on endothelial cells, promoting rolling and subsequent extravasation of inflammatory cells. 52 Accordingly, DeGrendele et al. previously demonstrated that application of a blocking antibody directed against CD44 prevents extravasation of V B 8 ϩ T cells into the peritoneal cavity induced by intraperitoneal injection of SEB. 16 Therefore, we analyzed liver sections to investigate whether the injection of LMW-HA inhibits the accumulation of inflammatory cells in a mouse model of Tcell-dependent liver injury. We neither found any difference in the number of CD44 ϩ or CD4 ϩ cells accumulating in livers of LMW-HA-pretreated, subsequently Con A-treated mice versus saline-pretreated mice, nor an inhibition of Con A hepatitis by injection of blocking antibodies directed against CD44 (clones used in our study: KM81, IM7, or KM201; data not shown). A previous study attributed the protective effects of LMW-HA to depletion of hepatic NK T cells by inhibition of CD44-HA interactions, thereby preventing P. acnes/LPS-mediated hepatic damage. 33 However, the authors did not verify the protective effect of NK T-cell depletion by injection of anti-NK1.1 monoclonal antibody or by usage of CD1d-deficient mice, which lack NK T cells, thereby excluding other protective mechanisms induced by LMW-HA, e.g., that LMW-HA rather acts as a signaling molecule than by inhibition of leukocyte accumulation in inflamed liver.
It is known from in vitro experiments that LPS and LMW-HA induce a comparable pattern of genes in macrophages, 25 possibly reflecting that both stimulants use equal postreceptor signal transduction pathways. Plasma levels of the proinflammatory cytokines, i.e., TNF, IL-6, and IFN-␥, were significantly reduced in PEA/LPS-injected mice pretreated with LMW-HA. This was not the result of enhanced production of the anti-inflammatory cytokine, IL-10, because IL-10 was also significantly suppressed. Thus, the hepatoprotective action of LMW-HA against PEA/LPS was rather the result of LMW-HA-induced tolerance of macrophages toward LPS than of enhanced levels of anti-inflammatory mediators. Surprisingly, despite a significant attenuation of hepatic damage, we could not find any differences in the plasma levels of TNF, IFN-␥, IL-2, IL-6, or IL-10 in Con A-treated mice as compared with mice that had been pretreated with LMW-HA. The fact that the classical T-cell-derived cytokine, IL-2, was not reduced by LMW-HA treatment is in line with our in vitro experiments demonstrating that LMW-HA does not inhibit the Con A-induced proliferative response of spleen cells. However, when we focused on intrahepatic TNF mRNA levels by use of real-time RT-PCR, we detected significantly reduced amounts of Con A-or PEA/LPS-induced TNF mRNA in LMW-HA-as compared with saline-pretreated mice. This observation is in line with our previous report, demonstrating the effect of Kupffer cell depletion on plasma and intrahepatic TNF levels: depletion of intrahepatic macrophages significantly reduced Con A-induced intrahepatic TNF, whereas plasma levels remained unaffected. 38 The different effect of LMW-HA pretreatment on systemic cytokine release in PEA/ LPS-as compared with Con A-treated mice might be in part a result of the fact that the hepatotoxins (i.e., PEA/LPS vs. Con A) activate distinct sources of TNF production. For example, in the Con A model, the source of the remaining circulating TNF might be the spleen, which has been described to be a major source of lymphocyte-derived IFN-␥ and TNF, 53 whereas PEA/LPS primarily activates macrophages, which became resistant toward LPS. Thus, the protective effect of LMW-HA fragments against Con A-and PEA/LPS-induced hepatic damage is likely the result of an impaired ability to activate intrahepatic macrophages.
Consistently, the most potent transcription factor of proinflammatory cytokines in inflammatory cells, i.e., NF-B, 48 was inhibited by LMW-HA pretreatment as demonstrated by EMSA. However, the fact that GalN/rmuTNF-induced hepatic failure, which is independent of endogenously produced cytokines and cellular infiltration, was also inhibited by LMW-HA demonstrates that, apart from resistance of macrophages toward proinflammatory stimuli, LMW-HA also exerts its hepatoprotective effect on the target cell level. GalN/ rmuTNF-induced hepatic injury is characterized by direct TNF-induced hepatocellular death under conditions of GalNinduced transcriptional arrest. 54 Pretreatment of animals with LMW-HA significantly reduced GalN/rmuTNF-induced release of plasma transaminases and prevented the characteristic histologic changes, i.e., massive pericentral confluent necrosis. GalN/rmuTNF treatment is associated with an increase of intrahepatic caspase-3 activity, which is a central feature of hepatic damage. Caspase-3 is a critical down-stream effector protease in the caspase cascade. 55 LMW-HA inhibited GalN/ rmuTNF-induced increase of caspase-3 activity. The factor that mediated the inhibition of caspase-3 activation appears to be regulated by NF-B, because inhibition of NF-B activation by PDTC restored the GalN/rmuTNF-induced increase of caspase-3 activity. Interestingly, LMW-HA significantly reduced the hepatic accumulation of inflammatory CD45 ϩ cells. This effect was restored by PDTC. This might be the result of a mechanism described by Lawson et al., who demonstrated that parenchymal apoptosis causes LPS-primed leukocytes to transmigrate through the endothelial barrier. 56 Thus, reduction of rmuTNF-induced hepatic apoptosis by LMW-HA most likely reduces the hepatic accumulation of leukocytes. FIG. 11 . LMW-HA induces intrahepatic TNF production in mice. Mice were either treated with saline, LMW-HA, or PDTC plus LMW-HA. Livers were removed 1 hour after LMW-HA injection, and 10-m sections of these livers were double-stained by use of a polyclonal rabbit anti-mouse TNF Ab together with rat anti-mouse macrophage mAb (clone BM8). Primary antibodies were detected with a secondary swine anti-rabbit-IgG tagged with FITC (green fluorescence) and a secondary goat anti-rat-IgG tagged with Texas Red (red fluorescence). Co-staining is represented by yellow fluorescence. All sections were examined by confocal laser scanning microscopy. One example is shown for 3 independent experiments.
FIG. 12. Pretreatment of mice with rmuTNF confers resistance against TNF-mediated hepatotoxicity. BALB/c mice were pretreated with 10 g/kg rmuTNF 12 hours before injection of either GalN/rmuTNF, Con A, or PEA. In the case of GalN/rmuTNF and Con A, liver injury was detected 8 hours, and in the case of PEA-induced hepatotoxicity, 12 hours after treatment. Hepatic damage was measured by determination of plasma transaminases (ALT and AST). Data are expressed as the mean Ϯ SEM; n ϭ 3; *P Ͻ .05 vs. saline-pretreated mice.
According to the functional data concerning the involvement of NF-B in LMW-HA-induced hepatoprotection, we could clearly demonstrate that hyaluronan fragments induce rapid translocation of NF-B into hepatic nuclei in vivo. The observation that LMW-HA induces NF-B is an important issue, because NF-B has been described to play a critical role in the up-regulation of many cytokines essential to the immune response (e.g., TNF, IL-1, lymphotoxin, and IFN-␥). 48 Noble et al. presented a variety of studies concerning the macrophage-activating properties of LMW-HA of mouse as well as of primary human macrophages. They demonstrated that incubation of macrophages with LMW-HA in vitro induced activation and subsequent translocation of NF-B into the nucleus. Thus, incubation of macrophages with LMW-HA induces a wide spectrum of proinflammatory mediators, such as chemokines, 27 iNOS, 28 and TNF. 25 The data presented in our study corroborate these in vitro findings by demonstrating that LMW-HA injection rapidly induced circulating TNF in vivo. As shown by immunofluorescent staining, liver-resident macrophages (Kupffer cells) rapidly responded to in vivoinjected LMW-HA by producing TNF. This was also confirmed by quantification of intrahepatic TNF levels. This effect was not the result of contaminating LPS, because LPSresistant C57BL/10 ScCr mice exhibited significantly elevated TNF-protein levels as compared with saline-treated controls. If one focuses on the kinetics of the events, it becomes evident that LMW-HA-induced production of TNF by Kupffer cells is the initial event, which is followed by the translocation of NF-B into hepatocyte nuclei. In this scenario, TNF shifts liver target cells by activation of the antiapoptotic transcription factor, NF-B, from a TNF-sensitive to a TNF-resistant status. 57 Accordingly, NF-B has been described to be a survival factor for liver parenchymal cells, 58, 59 because it confers physiologic protection of hepatocytes from TNF/TNF-R1-mediated apotosis. 59 The concept of TNF-induced protection from apoptosis by activation of NF-B has already been described in vitro, as TNF/TNF-R1 interaction induces activation of NF-B via the receptor-associated adaptor proteins, TRAF2 and RIP, thereby shifting cells to a TNF-resistant status. 57 Consistently, mice pretreated with rmuTNF were protected from TNF-mediated acute liver failure induced by either GalN/rmuTNF, Con A, or PEA. Furthermore, PDTC restored the sensitivity of LMW-HA-pretreated mice toward GalN/rmuTNF-mediated hepatotoxicity. A direct interaction between LMW-HA and hepatocytes and subsequent NF-B translocation appears to be unlikely, because liver parenchy- FIG. 13 . Translocation of NF-B into hepatic nuclei after LMW-HA injection. The RelA (p65) subunit of NF-B was detected by immunofluorescent staining and subsequent analysis by confocal laser imaging. BALB/c mice were either treated with solvent as negative control or rmuTNF or LMW-HA or PDTC and LMW-HA. Livers were removed 1 hour after treatment. Ten-micrometer sections were incubated with a polyclonal rabbit anti-mouse Ab directed against the RelA (p65) subunit of NF-B. Binding sites were detected with a Cy3-labeled goat anti-rabbit Ab. All sections were examined by confocal laser microscopy. The depicted pictures are representative for the different groups; n ϭ 3.
FIG. 14. LMW-HA is hepatotoxic under conditions of transcriptional arrest. To compare the hepatotoxic potential of LMW-HA with LPS under conditions of transcriptional arrest induced by GalN, we injected GalN-pretreated mice with either LMW-HA or LPS, as compared with mice that were treated with GalN, LMW-HA, or LPS alone. Plasma transaminase activities were determined 8 hours after treatment. Data are expressed as the mean Ϯ SEM; n ϭ 3; * P Ͻ .05 vs. saline-, LMW-HA-, or LPS-treated mice. mal cells, in contrast to Kupffer cells and intrahepatic lymphocytes, do not express CD44. 60, 61 Interestingly, when injected into mice under metabolic inhibition of transcription, LMW-HA is not hepatoprotective, but highly proinflammatory by inducing hepatic injury comparable with the combination of GalN/LPS. These observations further support the hypothesis that LMW-HA-induced NF-B has proinflammatory (TNF-inducing), but antiapoptotic (indirect induction of cytoprotective proteins within target cells), properties.
We therefore propose a new cascade of events leading to the observed hepatoprotective properties of hyaluronate fragments, based on the data presented in our current study. We demonstrated that in vivo injection of proinflammatory LMW-HA fragments activates hepatic macrophages to produce TNF. If transcription is inhibited, the proinflammatory capacity of LMW-HA leads to fulminant liver failure. However, when injected alone, LMW-HA-induced TNF subsequently activates NF-B translocation in liver parenchymal cells, thereby most likely inducing the expression of antiapoptotic proteins, which in turn inhibit caspase-3 activation and hepatocyte death. In addition, pretreatment of mice with LMW-HA induces a hyporesponsive state in Kupffer cells, as shown by strongly suppressed Con A-or PEA/LPS-induced activation of NF-B and synthesis of TNF mRNA within the liver.
In summary, our current study provides new insights into the wide range of actions of lower-molecular forms of HA in vivo. The accumulation of LMW-HA fragments has often been described to reflect disturbances of sinusoidal endothelial cell functions under conditions of acute and chronic liver inflammation (acute alcoholic hepatitis, chronic viral hepatitis, fibrosis). 3 We demonstrate that LMW-HA fragments are not only of prognostic value, but also have potent biological properties in vivo by themselves, leading either to hepatoprotection or, under conditions of transcriptional arrest, to hepatic failure. As a consequence, LMW-HA pretreatment might be suitable to protect the liver from hepatoinflammatory side-effects of therapies such as tumor therapy with immunotoxins 62 or adenovirus-mediated gene transfer. 63 
